Resolution of the Advisory board “Prospects for study and use of eribulin in advanced breast cancer”
https://doi.org/10.18027/2224-5057-2017-2-100-104
Abstract
The article presents the results of the meeting of the Advisory board “Prospects for study and use of eribulin in advanced breast cancer”, held on May 16, 2017, to discuss new data on the eribulin mechanism of action, the Russian experience with eribulin in real clinical practice and obtain expert opinions on the perspectives of study of eribulin use for breast cancer.
About the Authors
E. V. Artamonova
N. N. Blokhin Russian Cancer Research Center, Moscow
Russian Federation
PhD, the Leading researcher of the outpatient chemotherapy department
Russian Federation
PhD, the Leading researcher of the outpatient chemotherapy department
L. V. Bolotina
P. Herzen Moscow Oncology Research Institute of National Medical Research Radiological Centre, Moscow
Russian Federation
PhD, the Head of the chemotherapy department
Russian Federation
PhD, the Head of the chemotherapy department
V. A. Gorbunova
N. N. Blokhin Russian Cancer Research Center, Moscow
Russian Federation
PhD, the Head of the chemotherapy department
Russian Federation
PhD, the Head of the chemotherapy department
I. A. Demidova
Moscow City Oncology Hospital № 62, Moscow
Russian Federation
PhD, the Head of the Molecular genetic laboratory
Russian Federation
PhD, the Head of the Molecular genetic laboratory
N. V. Zhukov
Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow;
N. I. Pirogov Russian National Research Medical University (RNRMU), Moscow
Russian Federation
Russian Federation
PhD, the Head of the department of optimization of treatment for adults and children with cancer
L. G. Zhukova
N. N. Blokhin Russian Cancer Research Center, Moscow
Russian Federation
PhD, the Leading researcher of the chemotherapy and combined treatment of malignant tumors department
Russian Federation
PhD, the Leading researcher of the chemotherapy and combined treatment of malignant tumors department
L. V. Manzyuk
N. N. Blokhin Russian Cancer Research Center, Moscow
Russian Federation
Professor, the Leading researcher of the outpatient chemotherapy department
Russian Federation
Professor, the Leading researcher of the outpatient chemotherapy department
T. Y. Semiglazova
N. N. Petrov Research Institute of Oncology, Saint Petersburg;
North-Western State Medical University named after I. I. Mechnikov, Saint Petersburg
Russian Federation
Russian Federation
Professor, the Head of the innovative methods of therapeutic oncology and rehabilitation department
Professor of oncology department
References
1. Инструкция по медицинскому применению препарата Халавен® (РУ ЛП-001782 от 28.07.2012, с изменениями от 08.02.2017). [Instruktsiya po meditsinskomu primeneniyu preparata Halaven® (RU LP-001782 ot 28.07.2012, s izmeneniyami ot 08.02.2017). (In Russ.)].
2. Towle M. J., Salvato K.A., Wels B. F. et al. Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions, Cancer Res., 2011, Vol. 71. No. 2, pp. 496–505.
3. Funahashi Y., Okamoto K., Adachi Y. et al. Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models, Cancer Sci., 2014, Vol. 105, No. 10, pp. 1334–1342.
4. Ueda S., Saeki T., Takeuchi H. et al. In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients a comparison to bevacizumab, Br. J. Cancer, 2016, Vol. 114, No. 11, pp. 1212–1218.
5. Yoshida T., Ozawa Y., Kimura T. et al. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial – mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states, Br. J. Cancer, 2014, Vol. 110, pp. 1497–505.
6. Ozawa Y., Okamoto K., Adachi Y. et al. Suppression of Metastasis and Improvement of Drug Distribution by Eribulin Mesylate, EORTC-NCI-AACR, Barcelona, 2014, Vol. 5, p. 17.
7. Goto V., Kashiwagi S., Asano Y. et al. Clinical verification of antitumor autoimmune response in eribulin chemotherapy for breast cancer, AACR, 2016 [Abstr. #5127].
8. Cortes J., O’Shaughnessy J., Loesch D. et al. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a Phase 3 open-label randomised study, Lancet 2011, Vol. 377, No. 9769, pp. 914–923.
9. Kaufman P.A., Cortes J., Awada A. et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and taxan, J. Clin. Oncol., 2015, Vol. 33, No. 6, pp. 594–601.
10. Pivot X., Marme F., Koenigsberg R., Guo M., Berrak E., Wolfer A. Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy, Annals of Oncology, 2016, Vol. 27, pp. 1525–1531.
11. Twelves C. et al. Efficacy and safety of eribulin in combination with capecitabine in patients with metastatic breast cancer: an openlabel, phase 2 dose-confirmation study. Presented at SABCS 2014, Abstract #P3-13-04.
12. Wilks S., Puhalla S., O’Shaughnessy J. et al. Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer, Clin. Breast Cancer, 2014, Vol. 14, No. 6, pp. 405–412.
13. Araki K. et al. Eribulin Should be a Candidate Strategy in Combination with Pertuzumab Plus Trastuzumab for Taxane Pretreated HER2-Positive Advance Breast Cancer, SABCS, 2016 [Abstr. P5-15-11].
14. Hardy-Bessard A., Brocard F., Leheurteur M. et al. ESMERALDA: Phase II trial evaluating the combination of eribulin (E) + bevacizumab (BEV) as first line chemotherapy in patients with metastatic HER2-negative breast cancer (MBC): a GINECO group study, ESMO, 2016 [Abstr. #3730].
15. Tolaney S., Savulsky C., Aktan G. Phase 1b/2 Study to Evaluate Eribulin Mesylate in Combination With Pembrolizumab in Patients With Metastatic Triple-negative Breast Cancer, SABCS, 2016 [Abstr. P5-15-02].
Review
For citations:
Artamonova E.V., Bolotina L.V., Gorbunova V.A., Demidova I.A., Zhukov N.V., Zhukova L.G., Manzyuk L.V., Semiglazova T.Y. Resolution of the Advisory board “Prospects for study and use of eribulin in advanced breast cancer”. Malignant tumours. 2017;(2):100-104. (In Russ.) https://doi.org/10.18027/2224-5057-2017-2-100-104
Views:
851
Email this article 